BNT165 / BioNTech - LARVOL DELTA

Immunogenicity and Protective Efficacy Induced by PfCSP-encoding RNA-LNP Malaria Vaccines BNT165b1 and BNT165c in Mice (ASTMH 2025) - P1, P1/2 | "Despite their positive public health impact, the efficacy of the approved malaria vaccines (RTS,S/AS01 and R21/Matrix-M) is limited and short lived...Finally, immunization with BNT165b1 or BNT165c partially protects mice against infection with PfCSP-expressing P. berghei sporozoites. These pre-clinical results support the ongoing evaluation of BNT165b1 and BNT165c in early phase clinical trials (NCT05581641 and NCT06069544)."

Preclinical • Infectious Disease • Malaria • IFNG • TNFA

Safety and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria (clinicaltrials.gov) - P1 | N=60 | Completed | Sponsor: BioNTech SE | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Malaria

Safety and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria (clinicaltrials.gov) - P1 | N=60 | Active, not recruiting | Sponsor: BioNTech SE

Trial completion date • Trial primary completion date • Infectious Disease • Malaria

Safety and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria (clinicaltrials.gov) - P1 | N=60 | Active, not recruiting | Sponsor: BioNTech SE | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Malaria

Safety and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria (clinicaltrials.gov) - P1 | N=60 | Recruiting | Sponsor: BioNTech SE | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Malaria

Safety and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria (clinicaltrials.gov) - P1 | N=60 | Not yet recruiting | Sponsor: BioNTech SE

New P1 trial • Infectious Disease • Malaria